Market Access/ News/ News AbbVie files continuous Parkinson’s therapy ABBV-951 in US Phil Taylor ABBV-951, AbbVie, drug delivery, neurology, Parkinson's disease 0 Comment AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms Share X AbbVie files continuous Parkinson’s therapy ABBV-951 in US https://pharmaphorum.com/news/abbvie-files-continuous-parkinsons-therapy-abbv-951-in-us/
News/ News/ R&D AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trial Phil Taylor ABBV-951, AbbVie, Duopa, neurology, Parkinson's disease 0 Comment AbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral Share X AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trial https://pharmaphorum.com/news/abbvie-preps-filings-after-abbv-951-tops-oral-parkinsons-drugs-in-trial/
ABBV-951, AbbVie, drug delivery, neurology, Parkinson's disease
0 Comment
